

NHA

State of the Stop Loss/Group Captive Market







At-A-Glance



Berkley Accident and Health

- Pioneer and market leader in Stop Loss Group Captives since 2008
- Headquarters in Hamilton, NJ
- Offices in 15+ cities across the U.S.
- Distribution through:
 Benefit Consultants | Agents and Advisors
 Captive Consultants | Brokers



W. R. Berkley Corporation

- Fortune 500 company (#367 as of June 2023)
- 55+ independent operating units
- Founded in 1967
- 7,500 employees worldwide on 5 continents



Strength and experience

¹Berkley Life and Health Insurance Company, as of July 2023

One of the largest blocks in the Stop Loss Group Captive market

15


years offering **Group Captive** solutions


45 different Stop Loss **Group Captive programs** **A+**

rated (Superior) by A.M. Best¹

Ward's 50

top-performing insurer for safety and consistency¹









Trends in Large Claims

Source: 2023 AON Study / Market Scan Data



Market

After the pandemic we expect medical claims costs to increase at an increasing pace

Medical inflation tends to lag overall inflation and expect pressure over the next few years:

- As medical contracts are renegotiated providers are securing higher increases
- Provider systems still stressed financially and low staffing after pandemic



Large Claims

Large claims under \$1M largely moderated during the pandemic while \$1M claims continued to increase:

Claims over \$1M continue to increase and now incidence of million-dollar claims exceed over 10 per 100K



Top Claims

The largest claims continue to be driven by complex care and neonates in 2021.

There were 8 neonate claimants over \$5M in Marketscan for 2021




While GCT treatments are increasing, the initial incidence rates are significantly lower than most pricing models anticipated:

Marketscan included 9
Zolgensma treatments
which is less than 1 per
million incidence. Most
pricing models expected
over 5 per million


Other high-cost therapies continue to increase rapidly

Clinical Underwriting – Projections by Primary Dx Category



Trends in Specialty Drugs – New Launches

Source: Reuters Survey



SEVERITY

- Median annual price for new drugs approved by FDA increased from 180K in 2021 to 220K in 2022 (+22%)
- Median price at first data point in 2008: only \$2,115

FREQUENCY

- Approved drugs with annual costs greater than 150K / year:
 - 9% in 2008
 - 47% by 2021





PHARMACY

Gene Therapy Pools and Exclusions

Emerging genetic therapies offer meaningful advancements in the treatment of chronic, life limiting conditions but also have the potential to bankrupt a health plan.

- With 8 currently approved genetic therapies and over 50 expected in the next four years, employers face unprecedented exposure to high-cost claims
- Gene therapies range in cost from \$1M \$3.5M per claim and although approved by the FDA have typically only demonstrated effectiveness based on small sample sizes.
- Many re-insurance carriers will limit their liability by either excluding coverage or shifting the bulk of the claim to employers. Emerging reinsurance pools provide coverage for specific gene therapies and may offer employers an opportunity to provide coverage.
- USI recommends evaluating exclusion of all other gene therapies to reduce health plan exposure.

Gene Therapy Pooling Solutions								
Product	Gene Therapy Solution administered by Stealth an Amwins Company	Evernorth Embarc Benefit Protection® Administered by eviCORE	Optum Gene Therapy Risk Protection	PayRx	PreserveRx (Prime Therapeutics / BCS Insurance Co.) High deductible stop loss for large self-funded employers that include protection from FDA- approved, high-cost gene therapies S2M baseline deductible; \$500K step-down deductible for claimants receiving Zolgensma,			
Description	 First dollar reimbursement for cost incurred by the plan sponsor and then reimbursement for stop loss above deductible up to max Lifetime max payable per covered person varies by drug Excludes cell therapies 	First dollar coverage Removes drug claim from experience, eliminating impact on future renewals Not experienced rated Surplus calculated on entire pool, applied by group pro rata - calculated and paid retrospective after year end	 Narrow reinsurance product similar to Evernorth Embarc Benefit Protection® Includes care management services to support member navigation of the process and therapy administration Optum notes it will 	 MGU for High-Cost Advanced Therapies (HCATs) Utilizes predictive analysis to forecast future risk Participating contract only (upside only) \$100K qualifier, then first dollar coverage 80/20 No new lasers or 				

Impact and Benefits:

- Existing genetic therapies are available to less than 0.5% of the population.
- As therapies expand it is expected that ~1.2% of the population will be impacted.
- At that time, expected cost to the industry will be \$16 PMPM, with some employers exposed to millions of dollars in claims.

Identifying Your Exposure and Offering Solutions



UNDERWRITING & ANALYTICS

USI Stop Loss Consortium

USI leverages market size and underwriting expertise to negotiate best in class reinsurance contracts for USI clients

BERKSHIRE HATHAWAY INC.

- The USI Stop Loss Consortium includes the industry's largest reinsurance carriers
- The USI Stop Loss Consortium features:
 - No new lasers at renewal with specific rate caps ranging from 40% to 55%
 - Provisions to ensure that stop loss coverage is aligned with benefits plan
 - Dividend eligible contracts and early rate locks
 - AM Best "A" rated carriers only

uSI Stop	Loss	Consortium
00.010p		0011001110111

USI Stan Lass Cancartium		\sim							
USI Stop Loss Consortium			Direct		Direct			Direct	Direct
			A+ (Superior)		A (Excellent)		A (Excellent)		A++
								Yes	Yes
	CARRIER 1	•	CARRIER 2	CAR	RIER 3	CARRIER 4		200	50
Carrier Type	Direct		Direct	Direct		Direct	Direct		V
AM Best Rating	A+ (Superior)	A	(Excellent)	A (Excellent)		A+ (Superior)		ľ	
Top 10 Carrier	No		Yes	Yes		Yes			50% rate cap
Min. # of EES for a quote	100		100	50		35 (minimum in most states)		40%	for a 6% premium increase
No new lasers (NNL) at renewal	Included (as long as the case meets the minimum spec deductible level and premium requirements.		✓	·		√ Included (8% load, 40% cap)			Can be offered on a case by case basis
		40%	first renewal,	•50% for a 6% p	premium increase				

55% for a 5% premium increase

85% for a 3% premium increase 47% or 39%

Impact and Benefits:

- Save up to 15% of fixed insurance cost, or an estimated 1-3% of total program cost
- Eliminate exposures to costly lasers typically greater than \$100,000
- Best in class contractual provisions
- Ability to shop reinsurance market without member disruption















Best in Class Stop Loss Coverage and Contract Terms

Considered on a case-by-case basi



What is a Captive?



A Captive is a medium for taking risk.



Single Parent Captive

It can be formed by a single company



Group Captive

Or by multiple companies

What is a Group Captive?

A Group Captive can be made up of companies in the same industry or different:



Same industry



Different industries, sizes, or regions

What are Group Captives?

They Are:

- Alternative risk strategy for employers
- A financial strategy, <u>not</u> a benefits strategy
- It allows employers to *retain, share,* and *transfer* the financial risk for their self-funded health plan
- It lets small- to mid-size employers provide health benefits like a large employer

Why do Group Captives exist?

Group Captives exist to give employers:

- ✓ Control
- ✓ Lower overhead/inefficiency from insurance carriers
- ✓ Long-term stability
- Capacity
- Data transparency
- ✓ Collaboration/best practices

Why are Captives Proliferating?

Control and Engagement

Results = **Flexibility Long Term** to **Financing Customize Strategy Collaboration** Reduced **Volatility By** and **Scaling Innovation**


How is HRIC Group Captive Structured?

Risk is *retained*, *shared*, or *transferred*, depending how unpredictable and costly it is


LARGEST RISKS ARE TRANSFERRED TO STOP LOSS INSURER

MIDDLE LAYER IS SHARED WITH OTHER EMPLOYERS

SMALLEST RISKS ARE KEPT BY EMPLOYER



Relationship of Parties



Berkley's value to our members


Savings and customer satisfaction

1.5%

Members' annual cost increases were 1.5% lower than projected medical trend¹



Members' self-funded retention (SFR) claim costs were 8% lower than projected²





¹ 2016-2020 internal data, comparison of EmCap members' actual self-funded retention (SFR) claims vs. projected claims prior to start of plan year

² 2012-2022 internal data, comparison of EmCap members' actual self-funded retention (SFR) claims vs. projected claims prior to start of plan year ³ As of 1/1/23, based on active group captive programs with 2022 effective dates. Retention by premium.

Berkley's value to our members

Outstanding financial results



¹ Exceeded financial expectations means having loss ratios of 98% or lower. Did not meet or exceed financial expectations means having loss ratios of 102% or higher. No programs during this time period met on-target financial expectations with loss ratios between 98.1% and 101.9%. Calculations based on ceded layer loss ratios of active programs from 1/1/09 to 5/31/23 with at least 3 years of experience.




Berkley's value to our members

Lower large claims

Members of Group Captive programs averaged 22 large claims per 10,000 employees vs. 25 for Stop Loss policyholders not in a Captive.

Stop Loss Claims over \$250,000 per 10,000 employees







UNDERWRITING & ANALYTICS

Proprietary HRIC Captive

Employer Health Plan Risk Transfer

Retain, Share, Transfer.






January 2022



Proprietary HRIC Captive


Captive Loss Ratio





Proprietary HRIC Captive

Captive Distributions






UNDERWRITING & ANALYTICS


Springbuk Claims Analytic System

Incentivized Physician Engagement

Targeted Disease Management

Closure of Gaps in Care










Risk Management Roadmap – Need for PHM







POPULATION HEALTH MANAGEMENT FOR HOSPITALS

Domestic Care Management Programs

USI's assists hospital case managers in optimizing domestic case management programs to drive positive health outcomes and deliver claim savings.

- Hospitals are in a unique position to leverage onsite services to create or optimize domestic disease management programs for their employees.
- USI evaluates a variety of <u>claims data management tools</u> designed to assist hospital
 case managers to identify opportunities to introduce employees to <u>domestic disease</u>
 management programs.
- Plan designs and reimbursement strategies are created to <u>incentivize employees to</u> <u>participate</u> in appropriate care.
- USI communication specialists provide platforms to <u>drive domestic utilization</u>.



USI population health managers will assist the hospital in accessing external programs when domestic care is not available or certain services to support the management of it need to be augmented.

Impact and Benefits:

- Estimated cost avoidance can range from 3-5% of annual premium and significantly reduce long-term trend
- Cost neutral incentive design
- <u>Early detection and avoidance</u> of catastrophic claims
- Savings are case specific based on client's strategic goals and in house services
- By driving care within the domestic network, the hospital may recognize additional revenue.

Early Intervention Significantly Reduces Long Term Cost

Questions?

2/22

These examples are illustrative only and not indicative of actual past or future results. Stop Loss is underwritten by Berkley Life and Health Insurance Company, a member company of W. R. Berkley Corporation and rated A+ (Superior) by A.M. Best, and involves the formation of a group captive insurance program that involves other employers and requires other legal entities. Berkley and its affiliates do not provide tax, legal, or regulatory advice concerning EmCap. You should seek appropriate tax, legal, regulatory, or other counsel regarding the EmCap program, including, but not limited to, counsel in the areas of ERISA, multiple employer welfare arrangements (MEWAs), taxation, and captives. EmCap is not available to all employers or in all states.